脱氨基酸及其在阿尔茨海默病聚合物中的交叉链接
Samuel W Markovich1, Brian L Frey1, Mark Scalf1
1Department of Chemistry, University of Wisconsin-Madison; Madison, WI 53706, USA.
Brain communications
|January 30, 2025
概括
新的研究揭示了阿尔茨海默病 (AD) 大脑聚合物的脱氨基酸 (DHAA) 修饰. 这些修改形成蛋白质交叉链接,可能导致AD的聚合特征.
科学领域:
- 蛋白质组学是指蛋白质组学.
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 病理包括蛋白质聚合物的积累.
- 翻译后修改 (PTMs) 涉及影响蛋白质聚合.
- 脱氨基酸 (DHAA) 是一种罕见的具有反应性基的PTM,能够形成蛋白质交叉链接.
研究的目的:
- 调查阿尔茨海默病蛋白质聚合物中DHAA修饰的存在和作用.
- 在AD脑样本中识别由DHAAs修改的蛋白质和特定位点.
- 探索DHAA诱导的交叉链接对AD病变的贡献.
主要方法:
- 基于质谱的蛋白质组学被用来分析来自人类AD大脑样本的蛋白质聚合物.
- 与聚合物丰富分数和可溶性蛋白质分数之间的DHAA修饰位点的比较.
- 通过与细胞核友的反应形成的DHAA结合物的识别.
主要成果:
- 在AD大脑聚合物中的171种蛋白质上发现了404个DHAA修饰位,明显高于可溶性分数.
- 鉴定了11个DHAA诱导的蛋白质交叉链,其中3个在Tau蛋白中发现,在AD样本中数量增加了10倍.
- 许多DHAA修饰的蛋白质参与AD或蛋白质聚合失调的途径.
结论:
- 在阿尔茨海默氏症大脑蛋白质组中,DHAA的修饰是普遍存在的,并有助于蛋白质组复杂性.
- DHAA衍生的蛋白质交叉链接是AD病理学的重要特征.
- 这些交叉链接可能在促进阿尔茨海默病中的蛋白质聚合中发挥关键作用.
更多相关视频
09:00Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain
Published on: April 28, 2022
3.0K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.2K
相关概念视频
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:26Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160